Company Focus
Baxter
Latest Baxter News
Pharmaceutical
Russia has faced with the shortage of oncology drug Uromitexan (mercapto ethane sulphonacid; mesna), for which last deliveries to the country were in the spring of 2023, reports The Pharma Letter’s local correspondent. 15 May 2024
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs.
Latest News & Features of interest to Baxter
Biotechnology
Refoxy Pharmaceuticals has raised 9.1 million euros ($10 million) in seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), with support from Apollo Health Ventures and others. 4 December 2024
Pharmaceutical
Maze Therapeutics, a California-based biotech, has raised $115 million in a series D financing round co-led by Frazier Life Sciences and Deep Track Capital. 4 December 2024
Biotechnology
Roivant Sciences portfolio company Kinevant Sciences today revealed its Phase II study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. 3 December 2024
Pharmaceutical
Japanese pharma major Takeda has agreed an exclusive licensing agreement with US pharma Keros Therapeutics to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. 3 December 2024
Pharmaceutical
Suzhou’s Atom Therapeutics, has inked a deal with China Medical System (CMS) to commercialize lingdolinurad (ABP-671) in China, Hong Kong, and Macao. 3 December 2024
Biotechnology
California’s XOMA Royalty Corporation has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 million acquisition of Pulmokine, a privately-held company. 3 December 2024
Biotechnology
Nearly seven years after its founding, Senti Biosciences has announced promising results from its Phase I trial for SENTI-202. 3 December 2024
Biotechnology
French immunotherapy company OSE Immunotherapeutics announced that it has strengthened the company’s leadership and executive team with two new appointments. 3 December 2024
Pharmaceutical
The world’s hematologists are packing their bags in preparation for a visit to San Diego, California, for the American Society of Hematology (ASH) Annual Meeting and Exposition. Which companies’ data will they be looking out for? And which might take them by surprise? Our guide below offers a preview of some of the major presentations coming up. 1 December 2024
Biotechnology
Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval for its cardiomyopathy drug Attruby (acoramidis). On the research front, Biohaven posted disappointing data for its spinal muscular atrophy (SMA) and obesity candidate taldefgrobep. Also, PTC Therapeutics released new Phase II data on its investigational amyotrophic lateral sclerosis drug utreloxastat that missed its goal. Also of note, Arrowhead Pharmaceutical entered into an agreement, potentially worth $11 billion, granting rights to Sarepta Therapeutics for a multiple clinical program in the area of muscle, CNS and lung disease. 1 December 2024
Latest In Brief for Baxter
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Latest Relevant Ones To Watch News
California’s XOMA Royalty Corporation has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 million acquisition of Pulmokine, a privately-held company. 3 December 2024
28 November 2024
26 November 2024
19 November 2024
5 November 2024
30 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze